

In the Specification:

After the heading --**Cross Reference to Related Applications**-- please amend the paragraph thereafter as follows:

--This application is a Continuation application from U.S. Patent Application Serial No. 09/942,188 filed August 29, 2001, which is a divisional application from Serial No. 09/412,701, filed October 5, 1999, now Issued U.S. Patent No. 6,403,657 issued June 11, 2002, the entire contents all of which are hereby incorporated by reference in their entirety.--

Please replace the paragraph beginning on page 9, line 19, with the following rewritten paragraph:

--Within the comprehensive pharmacologic therapy for treatment of obesity the use of Phentermine and/or Diethylpropion in generic form, should be taken concurrently with Citalopram (Celexa), to treat exogenous obesity. Medication combinations that may be used are "Phentermine and Citalopram", "Diethylpropion and Citalopram", and Phentermine, Diethylpropion, and Citalopram". As is known in the art Celexa® is available from Forest Laboratories, Inc., of New York, New York, and/or Forest Pharmaceuticals, Inc., of St. Louis, Missouri. Citalopram is a racemic mixture of both the enantiomers S- and R- Citalopram. The S-Citalopram enantiomer is biologically active while the R-enantiomer is inactive. As is known in the art the S-Citalopram enantiomer is the SSRI chemical utilized in treating patients. The active S-enantiomer of Citalopram may be separated from the inactive R-enantiomer Citalopram and individually utilized in treating patients for weight loss. The chemical name for Citalopram is Citalopram Hydrobromide; (RS)-1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalan carbonitrile, hydrobromide, having the chemical formula $C_{20}H_{22}BrFN_2O$.--